Back to User profile » Dr Khaled Elsayes

Papers published by Dr Khaled Elsayes:

Enhancement Pattern Mapping for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Nikzad N, Fuentes DT, Roach M, Chowdhury T, Cagley M, Badawy M, Elkhesen A, Hassan M, Elsayes KM, Beretta L, Koay EJ, Jalal PK

Journal of Hepatocellular Carcinoma 2024, 11:595-606

Published Date: 20 March 2024

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab

Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U

Journal of Hepatocellular Carcinoma 2022, 9:913-927

Published Date: 30 August 2022

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A

Journal of Hepatocellular Carcinoma 2021, 8:1129-1145

Published Date: 9 September 2021

Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma

Moawad AW, Elsayes KM, Benamar F, Rao K, Sun J, Szklaruk J

Journal of Hepatocellular Carcinoma 2020, 7:331-335

Published Date: 18 November 2020

Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging

Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM

Journal of Hepatocellular Carcinoma 2020, 7:77-89

Published Date: 23 April 2020

LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance

Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB

Journal of Hepatocellular Carcinoma 2019, 6:49-69

Published Date: 5 February 2019

Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM

Journal of Hepatocellular Carcinoma 2018, 5:61-73

Published Date: 27 June 2018

Liver Imaging Reporting and Data System: an expert consensus statement

Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB

Journal of Hepatocellular Carcinoma 2017, 4:29-39

Published Date: 17 February 2017

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC

OncoTargets and Therapy 2016, 9:773-780

Published Date: 15 February 2016

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO

Journal of Hepatocellular Carcinoma 2016, 3:1-7

Published Date: 5 February 2016